Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)
暂无分享，去创建一个
V. de Lédinghen | Y. Yazdanpanah | D. Neau | M. Dupon | P. Morlat | S. Pol | F. Raffi | C. Michelet | T. Allègre | P. Perre | É. Bellissant | L. Cotte | F. Bailly | K. Lacombe | G. Pageaux | S. Chevaliez | M. Valantin | I. Poizot-Martin | L. Alric | A. Chéret | V. Leroy | P. de Truchis | É. Rosenthal | J. Reynes | L. Piroth | D. Zucman | D. Salmon-Céron | A. Simon | F. Marcellin | S. Dominguez | M. Carrieri | A. Lafeuillade | R. Garraffo | E. L. Pabic | E. Mortier | A. Renault | S. Métivier | C. Fougerou-Leurent | D. Batisse | L. Gérard | C. Tual | J. Moreau | Amélie Martin | C. Duvivier | E. Billaud | V. Jeantils | P. Girard | I. Rosa | H. Aumaître | E. Teicher | J. Chas | D. Makhloufi | A. Naqvi | A. Pailhé | J. Molina | T. May | I. Amri | M. Bourliere | E Le Pabic | Mustapha Ahmim | Julie Raimon | R. Thierry